Gregory Russotti
Fortune : 1 M $ au 31/05/2026
Fortune : 1 M $ au 31/05/2026
Gregory Russotti is currently an Advisor at Dynamk Capital LLC and Chief Technology & Manufacturing Officer at Century Therapeutics, Inc. since 2023.
Formerly, Dr. Russotti was VP, Cell Therapy Development and Operations at Celgene Corp.
from 2013 to 2019.
Education includes a doctorate from Rutgers State University of New Jersey conferred in 1996, and undergraduate and graduate degrees from Rensselaer Polytechnic Institute conferred in 1988 and 1990, respectively.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 12/06/2026 | 605 092 ( 0,34 % ) | 1 M $ | 31/05/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| CENTURY THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 01/01/2020 |
Dynamk Capital LLC
Dynamk Capital LLC Investment ManagersFinance Dynamk Capital invests in companies located in the United States. The firm focuses on the life sciences sector. It participates in early-stage transactions. | Consultant / Advisor | - |
| Sociétés | Poste | Fin |
|---|---|---|
| CELGENE | Corporate Officer/Principal | 31/12/2019 |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 5 |
|---|---|
Celgene Corp.
Celgene Corp. BiotechnologyHealth Technology Develops cancer and immunology drugs | Health Technology |
Rutgers State University of New Jersey
Rutgers State University of New Jersey Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Rensselaer Polytechnic Institute
Rensselaer Polytechnic Institute Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Dynamk Capital LLC
Dynamk Capital LLC Investment ManagersFinance Dynamk Capital invests in companies located in the United States. The firm focuses on the life sciences sector. It participates in early-stage transactions. | Finance |
Century Therapeutics, Inc.
Century Therapeutics, Inc. BiotechnologyHealth Technology Develops novel allogeneic living drugs for oncology that overcome the limitations of first-generation cell therapies | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national